We previously evaluated the prognostic value of U2AF1 mutations in MDS cohort samples, in which patients with U2AF1 mutations were found to have lower survival than patients with wild-type U2AF1 [10, 11]. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.